Objectives: Type 2 Diabetes Mellitus (T2DM) accounts for about 90% of all cases of Diabetes Mellitus.
Dyslipidaemia has been demonstrated to form a synergy with T2DM as risk factors for cardiovascular
events. This study aimed to determine the plasma levels of Lipids and Apolipoprotein B-100 among Type
2 Diabetic patients, assess the effects of Lipid Lowering agents, and to study the relationship, if any,
between these lipid parameters and glycemic control.
Methods: One hundred and fifty participants consisting of fifty T2DM patients on a lipid-lowering agent,
fifty newly diagnosed T2DM patients who are drug naïve (not on any anti-diabetic agent) and fifty
apparently healthy non-diabetic controls were recruited for this study. Fasting blood samples were
collected from all study participants for determination of Total Cholesterol (TC), LDL-C, Triglycerides
(TG), High-Density Lipoprotein (HDL-C) and Apo B-100.
Results: The results showed significant increases in plasma TC, LDL-C, TG and Apo B-100 with a
remarkable reduction in plasma HDL-C level in the Type 2 Diabetic drug naïve group compared with the
treatment and control groups. There was a significant positive correlation observed between serum Apo
B-100 and level of glycaemia in the T2DM drug naïve group.
Conclusion: This study further confirms the therapeutic benefits of lipid-lowering agents in reducing
Apo B-100 among T2DM patients. Furthermore, maintaining good glycaemic control reduces the risk for
the development of dyslipidaemia.